-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$6.50182.61% Upside
Inhibikase Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Inhibikase Therapeutics, Inc.?
Inhibikase Therapeutics, Inc. has been rated by research analysts at Jefferies, H.C. Wainwright in the past 90 days.